Chronic Lymphocytic Leukemia - The old and the new;Neues und Altes zur Chronisch Lymphatischen Leukämie

Therapeutische Umschau

Volumn 61, Issue 2, 2004, Pages 151-156

  Korte, Wolfgang ^a   Cogliatti, S ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FLUDARABINE; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; RITUXIMAB;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SMEAR; CANCER CYTODIAGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; HUMAN; PROGNOSIS;

EID: 1342304314     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.2.151     Document Type: Article

References (15)

1. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86: 2684-92.
2. de Lima M, O'Brien S, Lerner S, et al. Chronic lymphocytic leukemia in the young patient. Semin Oncol 1998; 25: 107-16.
3. Houlston RS, Catovsky D, Yuille MR. Genetic susceptibility to chronic lymphocytic leukemia. Leukemia 2002; 16: 1008-14.
4. Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002; 100: 2289-90.
5. Cogliatti SB, Schmid U. Who is WHO and what was REAL? Swiss Med Wkly 2002; 132: 607-17.
6. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-7.
7. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1799-801.
8. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-7.
9. Rai KR, Dohner H, Keating MJ, et al. Chronic lymphocytic leukemia: case-based session. Hematology (Am Soc Hematol Educ Program) 2001; 140-56.
10. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7.
11. Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003.
12. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-6.
13. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999; 91: 861-8.
14. Robak T. The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials. Leuk Lymphoma 2002; 43: 537-48.
15. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81: 121-6.